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2 PreDicta Consortium Member.Rhinoviruses (RVs) are ubiquitous human respiratory viruses, the major cause of common colds, acute
exacerbations of asthma and other respiratory diseases. The development of antibodies to RV following
primary infection is poorly understood and there is currently no RV vaccine available. We therefore used
mouse models of intranasal RV infection and immunisation to determine the induction, magnitude and
speciﬁcity of antibody responses. Strong cross-serotype RV-speciﬁc IgG responses in serum and broncho-
alveolar lavage were induced towards the RV capsid protein VP1. IgA responses were weaker, requiring
two infections to generate detectable RV-speciﬁc binding. Similarly two or more RV infections were nec-
essary to induce neutralising antibodies. Immunisation strategies boosted homotypic as well as inducing
cross-serotype neutralising IgG responses. We conclude that VP1 based antigens combined with adju-
vants may permit successful antibody-mediated vaccine design and development.
 2012 Published by Elsevier B.V.1. Introduction
RV’s are ubiquitous human pathogens of the respiratory tract.
They are the major cause of common colds and acute exacerbations
of airway diseases such as asthma and chronic obstructive pul-
monary disease (COPD), are responsible for approximately 50% of
virus-induced respiratory infections and half to two-thirds of
virus-induced asthma exacerbations (Greenberg, 2007; Johnston
et al., 1995). RV belongs to the single-stranded positive sense
RNA virus Picornaviridae family. The RNA genome is surrounded
by an icosahedral protein capsid comprising 60 copies of 4 struc-
tural proteins, the surface exposed VP1, VP2, VP3 and the buried
VP4 (Rossmann et al., 1985). One hundred distinct serotypes of
RV numbered 1–100 have been well characterised (Rhinoviruses:
a numbering system, 1967; Conant and Hamparian, 1968a,b) and
classiﬁed based on antibody neutralisation properties with guineaElsevier B.V.
espiratory Medicine, Imperial
l.: +44 20 7594 3764; fax: +44
cLean), s.johnston@imperia-
don Metropolitan University,pig antisera (Schieble et al., 1974). RV can be further grouped based
upon receptor usage with approximately 90% of serotyped strains
(major group) using ICAM-1 as the receptor to enter host epithelial
cells (Greve et al., 1989) whereas the minor group is known to ex-
ploit members of the low-density lipoprotein (LDL) receptor family
(Hofer et al., 1994).
In humans, protection against re-infection with RV is associated
with high levels of serotype-speciﬁc neutralising antibody both in
serum and respiratory secretions (Barclay et al., 1989). Vaccination
with RV preparations also induces neutralising antibodies in hu-
mans with IgA being the dominant antibody found in nasal secre-
tions whereas in serum IgG dominates (Knopf et al., 1970; Perkins
et al., 1969). In addition, high levels of RV-binding serum IgA cor-
relates well with total serum neutralising antibody levels, the lack
of development of a cold, and reduced viral shedding following
experimental RV infection (Barclay and Al-Nakib, 1987; Barclay
et al., 1988). The relative contributions of the various human IgG
and IgA subclasses to RV neutralisation has not been investigated
extensively although RV-binding IgG1, IgG4, and IgA1 levels rise
in response to RV infection and neutralising titres are correlated
with both IgG1 and IgA1 levels (Carey et al., 1992). In most cases,
neutralising antibodies generated to RV following immunisation
or infection are highly serotype-speciﬁc (Conant and Hamparian,
1968a,b), nevertheless in some cases, antibodies persisting from
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strated to cross-react with closely related RV serotypes and rarely
to result in cross-neutralisation (Fox, 1976). Thus, there are limited
data from humans supporting the development of vaccine strate-
gies that induce cross-serotype neutralising antibodies against
RV. However, the lack of a practical mouse model of RV infection
has been a major barrier for vaccine development and the investi-
gation of the fundamentals of RV antibody generation.
Complicating the study of antibody generation following RV
infection is the fact that humans experience frequent RV infections
throughout life (Turner, 1997) and therefore develop RV-speciﬁc
antibodies from an early age. Recently a mouse model of RV infec-
tion was developed (Bartlett et al., 2008). Intranasal infection of
minor (BALB/c) and major group (transgenic BALB/c expressing
mouse-human ICAM-1 chimaera) RV induced airway inﬂammatory
responses and viral replication was demonstrated in airway epi-
thelium (Bartlett et al., 2008). The major advantage of using a
mouse model of RV infection for our studies is, unlike humans,
mice are immunologically naive to RV and the development of
the humoral immune responses can be directly studied without
interference from cross reactive antibodies. We have now used this
model to characterise the induction of humoral immune responses
generated after single and multiple i.n. RV infections, studies that
are difﬁcult to perform in humans. We determined that antibody
responses were predominantly IgG, were directed against the RV
capsid protein VP1 and multiple RV infections were required to
generate neutralising antibodies. We also report that these re-
sponses can be augmented by mucosal CpG, as well as by systemic
immunisation with inactivated virus and adjuvant. The latter ap-
proach boosted serotype-speciﬁc as well cross-serotype neutralis-
ing antibody. Our ﬁndings demonstrate the utility of the mouse
model for investigating anti-RV humoral immunity and for deter-
mining the effect of vaccine strategies on the response to RV infec-
tion. VP1 based antigens combined with adjuvants have promise as
candidate vaccines to boost serotype-speciﬁc as well as cross-sero-
type neutralising antibodies.2. Materials and methods
2.1. Rhinovirus preparations
Serotypes RV1B, RV29 and RV16 were produced by culture in
HeLa cells as described previously (Bartlett et al., 2008). To inves-
tigate virus-speciﬁcity of antibody binding, control HeLa lysate was
prepared in an identical fashion from uninfected cells. RV prepara-
tions were inactivated by exposing them to UV light (1,200 mJ/cm2
for 30 min) as previously described (Bartlett et al., 2008). Recombi-
nant VP1 from RV14 and RV89 was expressed and puriﬁed as de-
scribed (Edlmayr et al., 2009, 2011).
2.2. Animals and experimental protocols
All animal work was in accordance with Project Licence PPL70/
6387, and performed according to regulations outlined by the
Home Ofﬁce, UK, in agreement with the Animals (Scientiﬁc Proce-
dures) Act 1986. Female 6–8 week old BALB/c mice were pur-
chased from Harlan and housed under appropriate SPF
conditions. RV infections were performed as described previously
(Bartlett et al., 2008). Brieﬂy, puriﬁed RV (1x106 TCID50) in a
50lL volume of PBS was introduced i.n. to groups of 4–6 isoﬂurane
anaesthetised mice.
2.2.1. Primary infection
Mice were infected i.n. with RV and sacriﬁced at time points up
to 18 days later.2.2.2. Secondary infection
Mice were infected i.n. with RV, left to resolve the infection for
30 days then re-infected i.n. with homologous or heterologous RV
serotypes and sacriﬁced at time points up to 16 days later. In some
experiments, mice were also administered 20 lg CpG oligonucleo-
tides (ODN 1826, Invivogen, Nottingham UK) i.n. 2 days before and
at the same time as the ﬁrst RV infection, left for 30 days and re-in-
fected i.n. with RV with analyses performed 7 days later.
2.2.3. Multiple infections
Mice were i.n. infected with RV1B on 5 separate occasions at
14–20 day intervals and sacriﬁced for endpoint analyses 4 days
after the ﬁnal infection.
2.2.4. Hyper-immunisation
Mice were immunised subcutaneously (s.c.) with 0.2 mL of a
solution containing equal volumes of Freund’s complete adjuvant
(FCA, Sigma Aldrich UK) and RV1B (2  106 TCID50). Mice were
then further immunised in a similar fashion using Freund’s incom-
plete adjuvant (IFA, Sigma Aldrich UK) and RV1B 4 further times at
monthly intervals. Control animals received adjuvant immunisa-
tions alone. Mice were infected i.n. with RV1B 1 month after the ﬁ-
nal immunisation and sacriﬁced 4 days later.
2.3. Elisa
Plates (96-well, Nunc MaxiSorp) were coated overnight at 4 C
with the puriﬁed RV preparations used for i.n. infections and HeLa
cell lysates diluted to a protein concentration of 5 lg/mL in PBS or
with puriﬁed recombinant VP1 proteins diluted to 1 lg/mL in PBS.
Plates were blocked for 2 h at room temperature by adding PBS
containing 0.05% Tween20 and 5% milk powder (PBST-milk) before
the addition of diluted serum or BAL samples and incubation over-
night at 4 C. Plates were washed with PBST and bound immuno-
globulins were detected using biotinylated rat anti-mouse IgG1,
IgG2a, IgG2b or IgA (BD Biosciences UK, Oxford UK) diluted
1:1000 before the addition of streptavidin-peroxidase (Invitrogen,
Paisley UK). Plates were developed using tetramethyl benzidine
(TMB) solution (Invitrogen, Paisley UK) as substrate and the optical
density read using a spectrophotometer at 450 nm with 570 nm
reference.
2.4. Immunoblotting
RV protein preparations were separated by reducing SDS–PAGE,
transferred to nitrocellulose membranes, blocked with PBST-milk
for 1 h at room temperature before diluted mouse or guinea pig
serum (V-113-501-558, purchased from ATCC) was added and
incubated overnight with shaking at 4 C. Bound serum IgG was
analysed using anti-mouse IgG or anti-guinea pig IgG coupled to
peroxidase (Sigma Aldrich UK). ECL advance (Amersham Biosci-
ences UK) was added to washed membranes which were then ex-
posed to X-ray ﬁlm and developed.
2.5. In vitro RV neutralisation assay
Mouse serum was serially diluted in a 96-well tissue culture
plate in DMEM containing 4%FCS then 100 TCID50 of RV1B or
RV16 was added before incubation with shaking at room temper-
ature for 1 h. 2  104 HeLa cells were added to each well and the
plates incubated at 37 C for 3 days before the cytopathic effect
(CPE) was inspected microscopically. CPE was measured by stain-
ing with crystal violet as described (Edlmayr et al., 2011). Guinea
pig antiserum speciﬁc for RV1B (V-113-501-558) or RV16 (V-
105-501-558) were purchased from ATCC and served as a positive
control for virus neutralisation.
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Mouse serum was diluted in PBS and allowed to mix with pro-
tein G Sepharose overnight at 4 C. After centrifugation to remove
the Sepharose beads and bound IgG, the unbound fraction contain-
ing IgA was retained and used in ELISA experiments. Depletion of
IgG from serum was conﬁrmed by showing loss of binding to RV
by ELISA.
2.7. Flow cytometry
Leukocytes from BAL and lungs were prepared as described pre-
viously (Bartlett et al., 2008). Approximately 5  105 cells were
suspended in FACS buffer (PBS containing 1% bovine serum albu-
min and 0.01% sodium azide), Fc receptors blocked with rat anti-
mouse CD16/CD32 (BD Biosciences UK, Oxford UK) for 20 min on
ice then stained with paciﬁc blue-conjugated rat anti-mouse CD3
(anti-CD3-PB) and ﬂuorescein isothiocyanate-conjugated rat anti-
mouse CD19 (anti-CD19-FITC) for 30 min on ice. The cells were
then washed several times before ﬂow cytometric analysis.
2.8. B cell ELISpot
Lung and mediastinal lymph node (MLN) leukocytes were pre-
pared as described previously (Bartlett et al., 2008). Detection of
total and RV-speciﬁc IgG and IgA production by B cells was per-
formed by ELISpot assay using kits purchased from Mabtech AB
(Nacka Strand, Sweden) and following manufacturer instructions.3. Results
3.1. Intranasal infection of mice with RV rapidly induces cross serotype
reactive IgG responses
We investigated the IgG responses generated to RV by BALB/c
mice following primary RV infection and re-challenge with homol-
ogous (RV1B) or heterologous (RV29) RV serotypes. Mice infected
with RV1B or RV29 made RV-speciﬁc serum IgG2a and IgG2b that
was detectable by ELISA after 8–16 days (upper panels of Fig. 1A–
D). RV-speciﬁcity was conﬁrmed by showing that both IgG2a
(Fig. 1A and C) and IgG2b (Fig. 1B and D) responses in wells coated
with RV preparations were signiﬁcantly greater than responses ob-
served in wells coated with HeLa cell lysates. The use of HeLa ly-
sate as an antigen was important given that RV was grown in
these cells and contained HeLa- and serum-derived proteins
against which antibodies may be generated. We also observed
RV-speciﬁc IgG that were serotype cross reactive since both serum
IgG2a and IgG2b were generated that bound RV1B after a single
RV29 infection (Fig. 1A and B). Following a single RV1B infection
only cross reactive serum IgG2b that recognised RV29 was de-
tected (Fig. 1C and D). These data reﬂect the high degree of capsid
protein homology (77% identity within VP1-VP2-VP3) that exists
between RV1B and RV29 which are both type A RV’s. Re-challenge
of mice by infection with RV1B or RV29 one month after the initial
RV1B infection generated increased RV-speciﬁc serum IgG re-
sponses that was detectable as early as 1 day after the second
infection and reached maximal levels after 4–8 days (lower panels
of Fig. 1A–D).
3.2. RV capsid protein VP1 is a major antibody target
To characterise the IgG binding to RV proteins by serum from
RV1B infected mice we performed western blot analyses. Proteins
within HeLa lysate, RV1B, RV29 and RV16 preparations were sepa-
rated by electrophoresis and probed with serum from RV1B in-fected mice or commercially available guinea pig antisera to
RV1B. Detection of the bound mouse IgG revealed a virus-speciﬁc
band of approximately 39 kDa common to RV1B, RV29 and RV16
(Fig. 2A left panel). The 39 kDa band was also observed in each
of the three RV preparations when probed with a commercially
available guinea pig antisera raised against RV1B (Fig. 2A right pa-
nel). It is likely that the 39 kDa band common to each RV prepara-
tion is VP1 since it has been shown previously to migrate at this
molecular weight (Skern et al., 1987). To conﬁrm the presence of
antibodies against VP1 in sera from mice infected twice with
RV1B we performed ELISA using puriﬁed recombinant VP1 from
RV serotypes RV14 and RV89 (Edlmayr et al., 2011) as the antigen
since recombinant VP1 from RV1B was unavailable. We observed
that mouse IgG2a from RV1B infected animals bound to the more
similar VP1 from RV89 (66% identity between RV1B and RV89
VP1) but not to VP1 from RV14 (43% identity between RV1B and
RV14 VP1) (Fig. 2B upper panels). IgG1 responses were not signif-
icant (Fig. 2B lower panels). These data support our notion that
antisera from RV infected mice primarily binds to the capsid pro-
tein VP1.
3.3. Multiple RV infections induce IgA responses
Two RV1B infections were required to generate signiﬁcant IgA
binding to RV1B as detected by ELISA (Fig. 3A). We observed that
both bronchoalveolar lavage (BAL) and serum contained detectable
RV1B-sepciﬁc IgA 4–8 days after the second RV1B infection
whereas a single RV1B infection did not generate signiﬁcant IgA re-
sponse to RV1B (Fig. 3A upper panel). RV1B serotype-speciﬁc bind-
ing was detected in BAL by day 4 post second infection whereas
cross reactive BAL IgA responses to RV29 were lower with signiﬁ-
cant binding not observed until 8 days after two RV1B infections
(Fig. 3A lower panel). For IgG isotype antibody responses no RV-
speciﬁc IgG was found in BAL after a single RV infection but signif-
icant binding of IgG2a and IgG1 to RV1B was detected 8–16 days
after two infections (Fig. 3B). These data imply that mice infected
with RV generate weak mucosal antibody responses or simply they
may reﬂect the fact that lower concentrations of IgA than IgG are
found in these samples. To determine if the difﬁculty in detecting
IgA was due to larger amounts of RV-speciﬁc IgG blocking access of
IgA to antigenic sites we treated serum from RV1B-infected mice
with protein G to remove IgG. This reduced the levels of IgG2a that
bound RV and permitted the easier detection of RV-speciﬁc IgA in
serum samples from mice infected multiple times with RV1B
(Fig. 3C). These data are consistent with the notion that mice in-
fected with RV generate both systemic and mucosal RV-speciﬁc
antibody responses and that the higher IgG levels can mask detec-
tion of IgA levels.
3.4. Lung and mediastinal lymph node B lymphocytes produce RV-
speciﬁc IgG
To investigate the source of RV-speciﬁc antibodies we analysed
B lymphocytes and their production of RV-speciﬁc antibodies fol-
lowing a single RV infection. We ﬁrst determined by ﬂow cytomet-
ric analyses that CD3-CD19+ B lymphocytes were found normally in
the lungs and that RV infection induced their appearance in BAL
after 4–7 days (SFig. 1A and B). Approximately 8.8% of BAL lympho-
cytes were B cells and their numbers were 100-fold lower than
found in lungs (SFig. 1A and 1B). By ELISpot, we were unable to de-
tect RV-speciﬁc IgG or IgA production by BAL cells, reﬂecting the
low frequency of B cells found in this anatomical location. How-
ever, similar analyses of unfractionated lung (Fig. 4A) and medias-
tinal lymph node (Fig. 4B) leukocytes showed that RV-speciﬁc IgG
was produced in a time-dependent manner. Thus, RV-speciﬁc IgG
production by B cells was maximal 10–18 days after a single
Fig. 1. Primary RV infections and homologous or heterologous secondary RV infections induce RV-speciﬁc serum IgG2a and IgG2b. BALB/c mice were infected i.n. with RV1B
or mock infected i.n. with PBS, left for 30 days then infected i.n. with RV1B or RV29, sacriﬁced at the indicated time points and serum obtained. Diluted mouse antiserum
(1:50) was added to ELISA plates coated with HeLa cell lysate (open symbols), puriﬁed RV1B (closed squares; A and B), or puriﬁed RV29 (closed circles; C and D) and binding
of IgG2a (A and C) and IgG2b (B and D) was assessed. Data are presented as the mean ± SEM (⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001 for HeLa vs. RV).
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greater frequency of production by cells from the lymph nodes.
RV-speciﬁc IgA was similarly produced albeit at much lower levels
than IgG (Fig. 4A and B), reﬂecting the masking effect of higher IgG
levels or the modest IgA responses observed in serum and BAL.
3.5. Mucosal CpG administration enhances IgG2a and RV-neutralising
antibody responses in response to RV infection
To promote neutralising antibody generation, we also treated
the mice infected with RV with Th1-promoting CpG oligonucleo-
tides (Fig. 5A). We determined the level of RV1B-speciﬁc serum
IgG by ELISA following two RV1B i.n. infections 30 days apart, the
ﬁrst infection directly following CpG or mock i.n. treatment. Anti-
sera from mice that were treated with CpG and infected with RV1B
displayed signiﬁcantly increased IgG2a responses but unaltered
IgG1 responses to RV1B (Fig. 5B). These data are consistent with
the known ability of CpG to promote Th1 immunity (Krieg, 2002)
and suggest that memory Th1 immunity to RV1B was encouraged
by mucosal CpG administration at the time of ﬁrst encounter with
RV1B. To determine if the increased Th1-associated IgG2a antibody
responses promoted by CpG resulted in production of neutralisingantibodies, we performed in vitro RV neutralisation tests. Antisera
from RV-infected and CpG-treated animals contained antibodies
that neutralised RV1B infectivity whereas antisera from mice in-
fected twice with RV1B in the absence of CpG failed to neutralise
(Fig. 5C). The neutralising property of the CpG-adjuvanted re-
sponse was serotype speciﬁc as neutralisation of RV16 was not ob-
served (Fig. 5C).
3.6. Immunisation with RV in Freund’s adjuvant generates cross–
serotype neutralising IgG
Having determined that mucosal CpG administration with live
RV1B infection promoted serotype-speciﬁc neutralising antibody
responses, we investigated whether systemic immunisations
might induce cross-serotype neutralising responses (Fig. 6A). Fol-
lowing subcutaneous immunisation with inactivated RV1B in Fre-
und’s adjuvant followed by a single intranasal infection with live
RV1B we observed high-titre RV-speciﬁc serum IgG2a and IgG1
(Fig. 6B). RV-speciﬁc serum IgA was not detected following this
immunisation protocol. Similarly to i.n. RV1B infections, immuni-
sation with RV1B in adjuvant generated strong serum IgG2a re-
sponses to recombinant RV89 VP1 but not to RV14 VP1 (Fig. 6C).
Fig. 2. Antisera from RV infected mice binds to the RV capsid protein VP1. (A)
Western blotting was performed to analyse IgG binding to HeLa lysate, RV1B, RV16,
and RV29 preparations using diluted antisera (1:500) frommice infected twice with
RV1B or diluted guinea pig antisera (1:1000) against RV1B. RV-speciﬁc band
suspected to be VP1 due to predicted molecular weight of 39 kDa is denoted by
arrow. (B) Antisera from naive mice (open symbols) or mice infected with RV1B
(closed symbols) were analysed by ELISA for IgG2a and IgG1 binding to puriﬁed
recombinant RV14 or RV89 VP1. Data are presented as serial dilutions of individual
antisera (n = 2, naive and RV1B infected).
Fig. 3. Induction of RV-speciﬁc IgA and mucosal antibody responses requires two
RV infections. BALB/c mice were infected with RV1B or mock infected with PBS, left
for 30 days then re-infected with RV1B, sacriﬁced at the indicated time points and
serum and BAL obtained. (A) Diluted serum (1:50) or BAL (1:4) from single (white
bars) or double (black bars) RV1B infected mice was added to ELISA plates coated
with puriﬁed RV1B (A, upper panel) or puriﬁed RV29 (A, lower panel) and assessed
for IgA binding. (B) Diluted BAL (1:4) from single infected (white bars) or double
RV1B infected (black bars) mice was also assessed for IgG2a and IgG1 binding to
RV1B. Data are presented as the mean ± SEM (⁄p < 0.05, ⁄⁄p < 0.01, for single RV1B
infection vs. double RV1B infections). (C) Serum from BALB/c mice infected ﬁve
times with RV1B was pooled and allowed to bind with protein G Sepharose to
deplete IgG. The unbound fraction (closed squares) was compared with untreated
serum (open squares) for levels of IgG2a and IgA binding to RV1B.
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tions in that the production of IgG1 that bound strongly to RV89
VP1 was induced (Fig. 6C). Antisera from immunised mice was also
analysed for binding to RV preparations by Western blot and was
shown to react similarly to sera from RV infected mice in that
mouse IgG bound to a RV-speciﬁc 39 kDa protein common to
RV1B, RV29 and RV16 preparations (arrow) consistent with VP1
(Fig. 6D). UV treatment of the RV preparations promoted loss of
antigenic epitopes by protein cross-linking/aggregation and did
not allow recognition by the antisera. We also determined the abil-
ity of these sera to neutralise RV in vitro. The antisera neutralised
RV1B at an endpoint dilution of 1:640 and also neutralised RV16
at an endpoint dilution of 1:40 whereas sera from mice adminis-
tered Freund’s adjuvant alone contained no neutralising activity
(Fig. 6E). RV1B challenge of immunised mice increased the num-
bers of CD3-CD19+ B lymphocytes found in BAL, when compared
to challenge of mice receiving adjuvant alone, without altering
the numbers of these cells found in lungs (SFig. 1C).
4. Discussion
Antibody responses to RV infection are not completely under-
stood and are difﬁcult to study in adults and children due to the
fact that humans are infected within months after birth and thencontinuously throughout life (Turner, 1997). As a result all humans
possess high levels of RV-speciﬁc antibodies that complicate stud-
ies into RV antibody-mediated immunity and vaccine develop-
ment. To avoid these problems, in this study we have
characterised the generation of antibody responses to RV following
infection and immunisation of mice. To our knowledge this is the
ﬁrst study to examine antibody responses to RV in vivo in an
immunologically naive host. Our results showed that signiﬁcant
cross serotype IgG responses in serum and BAL are generated in
Fig. 4. The frequency of RV-speciﬁc IgG producing B cells in lungs and lymph nodes are increased after RV infection. The frequency of RV1B-speciﬁc IgG and IgA producing B
lymphocytes in preparations of lung cells (A) and mediastinal lymph node cells (B) was determined by ELISpot assay at the indicated times following single i.n. RV1B infection
and in naive mice (Day 0). Data are presented as the mean ± SEM (⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, for IgG or IgA vs. time 0).
Fig. 5. Mucosal CpG administration augments RV-speciﬁc IgG2a responses. (A) BALB/c mice were administered i.n. with CpG 2 days prior to and on the day of RV1B i.n.
infection, left for 30 days then re-infected with RV1B and sacriﬁced 7 days later to obtain serum. (B) RV1B-speciﬁc IgG2a and IgG1 were determined by ELISA using antisera
from RV infected mice with (closed circles) and without (open circles) prior CpG treatment. Data are presented as the mean ± SEM of pooled antiserum from four animals
(⁄p < 0.05, ⁄⁄⁄p < 0.001, for RV1B infections vs. CpG/ RV1B infections). (C) Anti-RV sera generated in mice infected twice with RV1B with prior CpG treatment (CpG RV1B-RV1B)
or not (RV1B-RV1B) were titrated for in vitro neutralisation of HeLa cell infection by RV1B or RV16. Cultures were inspected microscopically and scored for the endpoint
dilution of sera that displayed complete protection from cytopathic effect (CPE).
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IgA responses and protective neutralising antibodies required re-
peat or multiple infections. The dominant antibody target for
cross-serotype recognition appeared to be the RV capsid protein
VP1. The mouse model also allows for investigations of speciﬁc
antibody responses following adjuvant administration, immunisa-
tion and RV challenge demonstrating its utility for the analyses and
development of RV vaccine approaches.
RV infections are common throughout life in humans making
RV one of the most successful human viral pathogens. It has been
estimated that children can get up to 12 RV infections per year andadults on average 2–5 infections (Turner, 1997). RVs exist as more
than 100 serotypes and serological ﬁndings demonstrate that pro-
tective antibodies generated following infection with one serotype
neutralise that serotype but provide little to no cross-protection to
other serotypes (Gwaltney, 1985). Because many serotypes of RV
are capable of circulating in the population simultaneously and
protective neutralising antibody is highly serotype speciﬁc, hu-
mans are frequently infected by RV serotypes even though they
may possess antibodies that are cross-serotype binding. Similarly,
as we have shown here with immunologically naive mice, single
RV infections generated cross-serotype binding but non-neutralis-
Fig. 6. Systemic immunisation of mice with RV generates cross-serotype neutralising serum IgG. (A) Antisera were generated by hyper-immunisation of mice with adjuvant-
immersed RV1B preparations or adjuvant alone before i.n. infection with RV1B. (B) Sera from adjuvant-treated (square symbols) and RV1B hyper-immunised BALB/c mice
(circular symbols) were analysed for IgG2a, IgG1 and IgA binding to HeLa lysate (open symbols) and puriﬁed RV1B (closed symbols) as antigens (Ag) by ELISA. Data are
presented as the mean ± SEM (⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, for hyper-immune sera binding RV1B vs. HeLa lysate). (C) IgG binding to recombinant VP1 was performed by titration of
serum and analysis by ELISA. Serum IgG2a (upper graphs) and IgG1 (lower graphs) from adjuvant-treated (open bars) and hyper-immunised mice (closed bars) were assessed
for binding to recombinant VP1 of RV14 (left) and RV89 (right). (D) Western blotting was performed to analyse IgG binding to HeLa lysate, RV1B, RV16, RV29, and UV-
inactivated RV preparations (UV1B, UV16, UV29) using diluted hyper-immune antisera (1:5000). (E) In vitro neutralisation of RV1B and RV16 was performed by serial titration
of pooled adjuvant-treated (ﬁlled squares) and hyper-immune (ﬁlled circles) BALB/c mouse antisera. Culture wells were inspected microscopically for cytopathic effect which
was quantitated by crystal violet staining and comparisons were made to wells containing HeLa cells alone (open circles) and HeLa cells infected with RV (open squares). Data
are presented as the mean ± SEM (⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, for hyper-immune serum vs. adjuvant only).
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neutralising antibody responses, two RV infections, Th1-promoting
adjuvants or immunisation with RV preparations in adjuvant were
required. This is in contrast to humans where a single infection is
often sufﬁcient to generate systemic and mucosal antibody re-
sponses capable of serotype-speciﬁc neutralisation (Douglas
et al., 1967), however since humans are frequently infected with
RV, it is likely that pre-existing pools of cross-serotype CD4 helper
T cells generated to these prior RV infections may help prime the
response to infection with a new RV serotype. This priming effect
is presumably also inﬂuenced by age, with young children and in-
fants having been exposed to signiﬁcantly fewer RV infections and
also being susceptible to more frequent RV infections (Taylor-Rob-
inson et al., 1963).
In humans, nasal antibodies of the IgA class have been shown to
be critical for protection against RV infection (Barclay and Al-
Nakib, 1987; Barclay et al., 1988) and patients with hypogamma-globulinemia develop persistent RV infections despite adequate
intravenous immunoglobulin (IVIg) replacement therapy further
highlighting the importance of secretory IgA (Kainulainen et al.,
2010). RV-speciﬁc secretory IgA is rarely present in the absence
of serum IgA and rarely absent when serum titres are high, there-
fore serum IgA should be a useful marker for the development of
mucosal humoral immunity to RV. We identiﬁed both mucosal
and systemic IgA responses to RV in mice but these required more
than one RV infection. These IgA responses were lower than the IgG
responses found in both serum and lung washes and are consistent
with our detection of a reduced frequency of B cells producing RV-
speciﬁc IgA compared to IgG in mediastinal lymph nodes and
lungs. Systemic immunisation of mice with RV in Freund’s adju-
vant did not promote IgA responses despite generating high-titre
neutralising IgG responses, suggesting that the route of RV admin-
istration and virus replication might be critical for optimal IgA
responses. However, Barnett et al. have previously demonstrated
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immunisation of mice with adjuvanted RV peptides (Barnett
et al., 1995, 1993). Nevertheless, a stronger IgG response in mice
may still be biologically signiﬁcant for RV infection since it is
known that secretory IgA protects the upper respiratory tract from
inﬂuenza but IgG is more important for protection of the lungs
(Renegar et al., 2004).
Our results indicate that the RV capsid protein VP1 is a major
target of the antibody response in infected mice. We did not detect
IgG to VP2 or VP3 despite the fact that we used infectious RV prep-
arations made from HeLa cell cultures in our assays and prepara-
tions made in this way have been shown to contain VP1, VP2
and VP3 (Johnston et al., 1998). For our studies, recombinant VP2
and VP3 were not available and the western blot analyses relied
on denatured and reduced viral antigen which may have lost po-
tential conformational epitopes within VP2 and VP3. Most antibod-
ies generated to RV infection in humans are directed against
epitopes found on surface-exposed structures of VP1, VP2 and
VP3 (Carey et al., 1992). Although there is evidence that the N–ter-
minus of VP4 may be transiently exposed at the capsid surface in a
process known as capsid breathing (Lewis et al., 1998) and anti-
bodies to this region of VP4 are cross-serotype protective (Katpally
et al., 2009), naturally occurring human antibodies to VP4 have not
been described. A recent study by Niespodziana et al. revealed that
children with RV-induced respiratory symptoms primarily gener-
ate IgG1 and IgA to N–terminal regions of VP1 and that responses
to VP2, VP3 and VP4 were signiﬁcantly lower (Niespodziana et al.,
2011). Interestingly the major epitope of these VP1-speciﬁc
antibodies is located inside the viral capsid and as such is a
non-neutralising epitope, suggesting that misdirection of antibody
responses in addition to strain variability can explain the escape of
RV to protective immunity (Niespodziana et al., 2011). In the cur-
rent study we have shown by western blotting of denatured RV
preparations and by immunoassay of recombinant puriﬁed VP1
that mice infected with RV generate IgG that binds to VP1 of multi-
ple RV serotypes. However this binding was sufﬁcient for neutral-
isation of just the homologous RV serotype suggesting the
importance of ﬁne speciﬁcity for VP1. Furthermore, the IgG
subclass IgG2a was found to be the dominant antibody class inter-
acting with recombinant VP1 even though we demonstrated both
IgG2a and IgG1 responses to intact viral preparations. IgG2a has
been reported to be commonly produced by mice in response to
viral infections (Coutelier et al., 1987) and may be a more effective
neutralising antibody due to its ability to ﬁx complement (Neuber-
ger and Rajewsky, 1981). Our data is highly suggestive of IgG2a tar-
geting a linear cross reactive epitope of VP1 following RV infection
of mice. Since VP1 is the dominant and most external of the RV
capsid proteins and contains receptor binding sites for both the
major and minor group RV (Vlasak et al., 2003), it is therefore
not surprising that mice infected with RV predominantly generate
antibodies to this region of the capsid. VP1 is a useful antibody
target as a recent study by Edlmayr et al., (Edlmayr et al., 2011)
has revealed that immunisation of rabbits with recombinant VP1
generates antisera with broad cross-serotype neutralising proper-
ties. Signiﬁcantly, there is a high degree of amino acid identity be-
tween VP1 within both type A and B RV serotypes and VP1 also
contains several conserved domains, the drug binding pocket for
pleconaril and two of the four neutralising immunogenic sites
targeted by antibodies (Laine et al., 2006; Ledford et al., 2004;
Rossmann et al., 1985; Sherry et al., 1986).
It is important to understand the development of antibody
responses to RV as young children are obvious vaccine candidates
for prevention of early recurrent RV infections which have been
reported to be associated with increased risk of asthma develop-
ment (Jackson et al., 2008) and RV-induced exacerbations of asth-
ma (Murray et al., 2006). In this regard, the study of antibodyresponses in mice infected or immunised with RV add to the cur-
rent limited knowledge regarding binding and neutralising anti-
body responses to RV in humans. We have established the utility
of the mouse model by demonstrating the induction of cross-sero-
type RV-speciﬁc antibodies following infection and the use of two
different adjuvant approaches to promote neutralising responses.
This is the ﬁrst in vivo study of the priming of antibody responses
to RV infection and taken together, these results and our model
system have important implications for RV vaccine design. Our
studies suggest that RV vaccine approaches need to target the lung
using deﬁned highly conserved RV epitopes to generate cross-sero-
type local mucosal IgA responses which may be more suitable for
protection than the systemic IgG responses often favoured. Further
studies, such as different strains of mice (e.g. C57Bl/6), the use of
mice transgenic for speciﬁc antibody genes (e.g. human Ig V
regions) or with disrupted IgG genes, other adjuvants, and the
transfer of immune serum to assess protection and subsequent
analyses in our model system will increase the understanding of
cross-protective antibody responses to RV and lead to the genera-
tion of a vaccine for this important human respiratory viral
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